Stuart Reports Initial Outcomes From Trial of Ophthalmic Solution for DED

Stuart Therapeutics releases initial results of phase 3 clinical trial evaluating ST-100 (vezocolmitide) ophthalmic solution for dry eye disease

ST-100 shows promise as a fast-acting treatment for dry eye disease, offering rapid relief and unique collagen repair mechanisms.

Stuart reports initial outcomes from trial of ophthalmic solution for DED

Stuart Therapeutics has reported initial findings from its Phase III trial of ST-100 ophthalmic solution for dry eye disease (DED).The post Stuart reports initial outcomes from trial of ophthalmic solution for DED appeared first on Clinical Trials Arena.

Phase 3 clinical trial results for ST-100 (vezocolmitide) ophthalmic solution, a novel dry eye candidate

ST-100 shows promise as a fast-acting treatment for dry eye disease, offering rapid relief and unique collagen repair mechanisms.

Stuart Therapeutics Announces Initial Results of Phase III Clinical Trial for ST-100 (Vezocolmitide) Ophthalmic Solution, a Dry Eye Disease Candidate

Stuart Therapeutics announced the initial results of its Phase III clinical trial evaluating ST-100 (vezocolmitide) ophthalmic solution for the treatment of dry eye disease (DED), which affects more than 30 million U.S. adults.   The 29-day randomized, double-blind, vehicle-controlled trial assessed a variety of endpoints, including a primary endpoint of a significant increase in the proportion of patients exhibiting a greater than 10mm improvem…